-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Medication-Related Risks
Pharmacological Treatment of Agitation in Persons With Dementia (British Journal of Clinical Pharmacology)
Summary A systematic review and meta‐analysis of pharmaceutical treatments for alleviating agitation in dementia has been performed. Regarding the efficacy and treatment acceptability of these medications, it is reported that: “Risperidone, SSRIs as a class and Dextromethorphan / Quinidine demonstrated … Continue reading →
Posted in Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Pharmacological Treatments, Quick Insights, Systematic Reviews
|
Tagged Agitation, Agitation and Aggression, Antidepressants, Antidepressants for Agitation and Psychosis in Dementia, Antipsychotics in Elderly People with Dementia, Asian Centre for Evidence Synthesis in Population Implementation and Clinical Outcomes (PICO): Monash University Malaysia, Atypical Antipsychotics, Australia, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, BPSD: Behavioral and Psychological Symptoms of Dementia, British Journal of Clinical Pharmacology, Center of Pharmaceutical Outcomes Research (CPOR): Naresuan University, Centre for Medicine Use and Safety: Monash University, Chulalongkorn University (Bangkok), Dementia-Related Agitation, Department of Clinical Pharmacy: Mahasarakham University, Department of Pharmacy Practice: Naresuan University, Department of Psychiatry: King Chulalongkorn Memorial Hospital, Dextromethorphan / Quinidine (DM/Q: Nuedexta™), Faculty of Medicine: Chulalongkorn University, Faculty of Pharmaceutical Sciences: Naresuan University, Faculty of Pharmacy and Pharmaceutical Sciences: Monash University, Haloperidol, Health and Well-being Cluster - Global Asia in the 21st Century (GA21) Platform: Monash University Malaysia, Interventions for BPSD, King Chulalongkorn Memorial Hospital, Kolling Institute of Medical Research: Royal North Shore Hospital, Mahasarakham University (Thailand), Malaysia, Managing Agitation, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Monash University, Monash University Malaysia, Mood Disturbances, Naresuan University (Thailand), Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Oxcarbazepine, Patient Safety, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Psychotropic Drugs, Psychotropic Medication, Psychotropic Prescribing, Reducing Agitation and Distress, Risperidone, Royal North Shore Hospital (Australia), School of Pharmacy: Monash University Malaysia, Selective Serotonin Reuptake Inhibitors (SSRIs), SSRIs: Selective Serotonin Reuptake Inhibitors, Systematic Reviews and Meta-Analyses, Thailand, University of Sydney
|
Leave a comment
Review of Non-Pharmacological Interventions for Dementia-Related Agitation: Including a Brief Analysis of the Risks and Benefits of Drug Treatments (Translational Psychiatry)
Summary A recently published literature review evaluates the best available evidence on the effectiveness of various non-pharmacological interventions for reducing dementia-related agitation. The author also briefly addresses current viewpoints on balancing the risks and benefits of pharmacotherapy in the management … Continue reading →
Posted in Acute Hospitals, Antipsychotics, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Local Interest, Management of Condition, Mental Health, Models of Dementia Care, New Cross Hospital, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Systematic Reviews, UK, Universal Interest, Wolverhampton
|
Tagged ACADIA Pharmaceuticals, Agitation, Agitation and Aggression, Alternatives to Antipsychotic Drugs, Animal Assisted Therapy, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Aromatherapy, Arts and Music in Dementia, Atypical Antipsychotics, Avanir Pharmaceuticals Inc (California), Behavioural Alternatives to Antipsychotic Drugs, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, Behavioural Variant Frontotemporal Dementia (bvFTD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Carbamazepine, Citalopram, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Cognitive Behavioral Therapy, Dementia-Related Agitation, Department of Medicine: Royal Wolverhampton NHS Trust, Describe Investigate Create and Evaluate (DICE) Approach, East Kent Hospitals University NHS Foundation Trust, Electroconvulsive Therapy for Agitation and Aggression in Dementia, Improving the Quality of Life for People With Dementia, Interventions for BPSD, Intra-Cellular Therapies, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Memantine, Mirtazapine, Mood Disturbances, Multisensory Stimulation, Music Therapy, Music Therapy for BPSD, Music-Based Therapeutic Interventions, Nature Publishing Group, Neuroleptic Discontinuation, Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Non-Pharmacological Management of Symptoms, Non-Pharmacological Treatments, Otsuka Pharmaceuticals Limited, Pharmacological Treatments, Potential Harms of Antipsychotic Use, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Quetiapine, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, Simulated Presence Therapy (SPT), Simulated Presence Therapy for BPSD, Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME), Translational Psychiatry, Withdrawal of Neuroleptic Medications
|
Leave a comment
MATCH-D: Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (Internal Medicine Journal / BMJ Open)
Summary The Medication Appropriateness Tool for Comorbid Health conditions in Dementia (MATCH-D) criteria were developed to provide consensus guidance on the use of medications for people with dementia. Full Text Link Reference Page, AT. Potter, K. Clifford, RM. [et al] … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Commissioning, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, International, Management of Condition, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Australia, BMJ Open, BMJ Publishing Group Ltd, Brighton and Sussex Medical School: University of Sussex, Centre for Education and Research on Ageing: University of Sydney, Comorbid Health Conditions in Dementia, Comorbidity, Comorbidity and Dementia, Complex Comorbidities, Concord Hospital (Sydney Australia), Dementia and Comorbidity, Dementia Comorbidities, Deprescribing, Drug-Drug Interactions, Faculty of Pharmacy: University of Sydney, Healthcare Provision for People With Dementia and Comorbidity, Inappropriate Prescribing, Internal Medicine Journal, Ireland, Managing Comorbidity and Complexity, MATCH-D: Medication Appropriateness Tool for Comorbid Health conditions in Dementia, Medication Appropriateness Tool for Comorbid Health conditions in Dementia (MATCH-D), Medication Management, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Multiple Comorbidities, Multiple Medications (Polypharmacy), New South Wales (Australia), Optimising Medications for Older People With Multiple Comorbidities, Optimising Prescribing and Deprescribing in Older Adults With Dementia, Over-Medication, Potentially Inappropriate Prescribing, Potentially Inappropriate Prescribing in Advanced Dementia, Royal College of Surgeons in Ireland, School of Allied Health: University of Western Australia, School of Medicine: University of Western Australia, School of Pharmacy: Royal College of Surgeons in Ireland, University of Sussex, University of Sydney, University of Western Australia, Western Australian Centre for Health and Ageing: University of Western Australia
|
Leave a comment
Common Medicines Associated With Dementia Risk (BBC News / JAMA Internal Medicine)
Summary A US study, published in JAMA Internal Medicine, concerning long-term use of anticholinergic-type drugs (those which block the neurotransmitter acetylcholine), in older people, has discovered an association with the risk of developing dementia. Higher doses and prolonged use of … Continue reading →
Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Practical Advice, Quick Insights, Statistics, Universal Interest
|
Tagged Acetylcholine, Anticholinergic Drugs, Anticholinergics, Bazian, BBC Health News, Behind the Headlines, Benadryl, Branta Foundation, Chlorpheniramine Maleate, Cumulative Anticholinergic Use (Dementia Risk Factor), Dementia Risk Factors, Dementia Risk Reduction, Department of Biostatistics and Epidemiology: Perelman School of Medicine, Department of Biostatistics: University of Washington, Department of Epidemiology: University of Washington, Diphenhydramine (Sleep Aid), Ditropan (Incontinence Drug), Division of General Internal Medicine: University of Washington, Division of Geriatric Medicine: University of Pittsburgh, Doxepin (Antidepressant), Doxepin Hydrochloride, Drug Side-Effects, Epidemiology, Epidemiology and Statistics, Group Health Research Institute: Seattle, Hay-Fever Treatments, JAMA Internal Medicine, Meclizine Hydrochloride, Medication-Related Risks, Modifiable Risk Factors, National Institute on Aging (NIA), National Institutes of Health (NIH), National Institutes of Health (US), Nytol, Olanzapine, Oxybutynin (Urinary Incontinence Drug), Perelman School of Medicine: University of Pennsylvania, Piriton (Antihistamine), Risk Factors, Risk Factors for Alzheimer's Diseease, School of Pharmacy: University of Washington, Seroxat (Antidepressant), Sleep Aids, Strong Anticholinergics Association With Incident Dementia, Total Standardised Daily Doses (TSDDs): Cumulative Exposure, United States, University of Pittsburgh, University of Washington, USA, Xybutynin Chloride
|
Leave a comment
